Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMISKOWIAK, K. W.
dc.contributor.authorBURDICK, K. E.
dc.contributor.authorMARTINEZ-ARAN, A.
dc.contributor.authorBONNIN, C. M.
dc.contributor.authorBOWIE, C. R.
dc.contributor.authorCARVALHO, A. F.
dc.contributor.authorGALLAGHER, P.
dc.contributor.authorLAFER, B.
dc.contributor.authorLOPEZ-JARAMILLO, C.
dc.contributor.authorSUMIYOSHI, T.
dc.contributor.authorMCINTYRE, R. S.
dc.contributor.authorSCHAFFER, A.
dc.contributor.authorPORTER, R. J.
dc.contributor.authorPURDON, S.
dc.contributor.authorTORRES, I. J.
dc.contributor.authorYATHAM, L. N.
dc.contributor.authorYOUNG, A. H.
dc.contributor.authorKESSING, L. V.
dc.contributor.authorVIETA, E.
dc.date.accessioned2018-07-05T18:06:18Z
dc.date.available2018-07-05T18:06:18Z
dc.date.issued2018
dc.description.abstractObjectivesCognition is a new treatment target to aid functional recovery and enhance quality of life for patients with bipolar disorder. The International Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force aimed to develop consensus-based clinical recommendations on whether, when and how to assess and address cognitive impairment. MethodsThe task force, consisting of 19 international experts from nine countries, discussed the challenges and recommendations in a face-to-face meeting, telephone conference call and email exchanges. Consensus-based recommendations were achieved through these exchanges with no need for formal consensus methods. ResultsThe identified questions were: (I) Should cognitive screening assessments be routinely conducted in clinical settings? (II) What are the most feasible screening tools? (III) What are the implications if cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, (II) use brief, easy-to-administer tools such as the Screen for Cognitive Impairment in Psychiatry and Cognitive Complaints in Bipolar Disorder Rating Assessment, and (III) evaluate the impact of medication and comorbidity, refer patients for comprehensive neuropsychological evaluation when clinically indicated, and encourage patients to build cognitive reserve. Regarding question (IV), there is limited evidence for current evidence-based treatments but intense research efforts are underway to identify new pharmacological and/or psychological cognition treatments. ConclusionsThis task force paper provides the first consensus-based recommendations for clinicians on whether, when, and how to assess and address cognition, which may aid patients' functional recovery and improve their quality of life.
dc.description.indexMEDLINE
dc.description.sponsorshipLundbeck
dc.description.sponsorshipAllergan
dc.description.sponsorshipOtsuka
dc.description.sponsorshipPfizer
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipBristol-Myers Siquibb
dc.description.sponsorshipBrain and Behaviour Foundation
dc.description.sponsorshipSpanish Ministry of Economy and Competitiveness
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipTakeda
dc.description.sponsorshipCOLCIENCIAS
dc.description.sponsorshipUniversidad de Antioquia-CODI
dc.description.sponsorshipNIMH
dc.description.sponsorshipSumitomo Dainippon
dc.description.sponsorshipAlkermes
dc.description.sponsorshipBristol Myers Squibb
dc.description.sponsorshipCANMAT
dc.description.sponsorshipCIHR
dc.description.sponsorshipDainippon Sumitomo Pharma
dc.description.sponsorshipJanssen
dc.description.sponsorshipSunovion
dc.description.sponsorshipTeva
dc.description.sponsorshipAB-Biotics
dc.description.sponsorshipAlexza
dc.description.sponsorshipAlmirall
dc.description.sponsorshipAngelini
dc.description.sponsorshipBristol-Myers Squibb
dc.description.sponsorshipCephalon
dc.description.sponsorshipEli Lilly
dc.description.sponsorshipFerrer
dc.description.sponsorshipForestResearch Institute
dc.description.sponsorshipGedeon Richter
dc.description.sponsorshipGlaxoSmith-Kline
dc.description.sponsorshipJanssen-Cilag
dc.description.sponsorshipJazz
dc.description.sponsorshipJohnson Johnson
dc.description.sponsorshipMerck
dc.description.sponsorshipNovartis
dc.description.sponsorshipOrganon
dc.description.sponsorshipPierre-Fabre
dc.description.sponsorshipQualigen
dc.description.sponsorshipRoche
dc.description.sponsorshipSanofi-Aventis
dc.description.sponsorshipSchering
dc.description.sponsorshipPlough
dc.description.sponsorshipServier
dc.description.sponsorshipShire
dc.description.sponsorshipSolvay
dc.description.sponsorshipCIBERSAM
dc.description.sponsorshipSeventh European Framework Programme (ENBREC)
dc.description.sponsorshipStanley Medical Research Institute
dc.description.sponsorshipUnited Biosource Cooperation
dc.description.sponsorshipWyeth
dc.identifier.citationBIPOLAR DISORDERS, v.20, n.3, p.184-194, 2018
dc.identifier.doi10.1111/bdi.12595
dc.identifier.eissn1399-5618
dc.identifier.issn1398-5647
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/27043
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofBipolar Disorders
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY
dc.subjectbipolar disorder
dc.subjectcognitive impairment
dc.subjectneuropsychological
dc.subjectrecommendations
dc.subjectscreening
dc.subject.otherrandomized controlled-trial
dc.subject.otherrating assessment cobra
dc.subject.otherfunctional remediation
dc.subject.otheri disorder
dc.subject.otherdepression
dc.subject.otherassociation
dc.subject.otherperformance
dc.subject.othercomplaints
dc.subject.otherreserve
dc.subject.othermemory
dc.subject.wosClinical Neurology
dc.subject.wosNeurosciences
dc.subject.wosPsychiatry
dc.titleAssessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryNova Zelândia
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryDinamarca
hcfmusp.affiliation.countryColômbia
hcfmusp.affiliation.countryJapão
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisoes
hcfmusp.affiliation.countryisoca
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisoco
hcfmusp.affiliation.countryisojp
hcfmusp.affiliation.countryisodk
hcfmusp.affiliation.countryisonz
hcfmusp.author.externalMISKOWIAK, K. W.:Rigshosp, Copenhagen Affect Disorder Res Ctr CADIC, Copenhagen Univ Hosp, Psychiat Ctr Copenhagen, Copenhagen, Denmark; Univ Copenhagen, Deparment Psychol, Copenhagen, Denmark
hcfmusp.author.externalBURDICK, K. E.:Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Boston, MA USA
hcfmusp.author.externalMARTINEZ-ARAN, A.:Univ Barcelona, Hosp Clin, Clin Inst Neurosci, IDIBAPS,CIBERSAM, Barcelona, Catalonia, Spain
hcfmusp.author.externalBONNIN, C. M.:Univ Barcelona, Hosp Clin, Clin Inst Neurosci, IDIBAPS,CIBERSAM, Barcelona, Catalonia, Spain
hcfmusp.author.externalBOWIE, C. R.:Queens Univ, Dept Psychol, Kingston, ON, Canada
hcfmusp.author.externalCARVALHO, A. F.:Univ Fed Ceara, Dept Clin Med, Fortaleza, Ceara, Brazil; Univ Fed Ceara, Fac Med, Translat Psychiat Res Grp, Fortaleza, Ceara, Brazil
hcfmusp.author.externalGALLAGHER, P.:Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England
hcfmusp.author.externalLOPEZ-JARAMILLO, C.:Univ Antioquia, Res Grp Psychiat, Dept Psychiat, Medellin, Colombia
hcfmusp.author.externalSUMIYOSHI, T.:Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Tokyo, Japan
hcfmusp.author.externalMCINTYRE, R. S.:Univ Toronto, Brain & Cognit Discovery Fdn, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
hcfmusp.author.externalSCHAFFER, A.:Univ Toronto, Dept Psychiat, Toronto, ON, Canada
hcfmusp.author.externalPORTER, R. J.:Univ Otago, Dept Psychol Med, Christchurch, New Zealand
hcfmusp.author.externalPURDON, S.:Univ Alberta, Dept Psychiat, Edmonton, AB, Canada
hcfmusp.author.externalTORRES, I. J.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
hcfmusp.author.externalYATHAM, L. N.:Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
hcfmusp.author.externalYOUNG, A. H.:Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
hcfmusp.author.externalKESSING, L. V.:Rigshosp, Copenhagen Affect Disorder Res Ctr CADIC, Copenhagen Univ Hosp, Psychiat Ctr Copenhagen, Copenhagen, Denmark
hcfmusp.author.externalVIETA, E.:Univ Barcelona, Hosp Clin, Clin Inst Neurosci, IDIBAPS,CIBERSAM, Barcelona, Catalonia, Spain
hcfmusp.citation.scopus117
hcfmusp.contributor.author-fmusphcBENY LAFER
hcfmusp.description.beginpage184
hcfmusp.description.endpage194
hcfmusp.description.issue3
hcfmusp.description.volume20
hcfmusp.origemWOS
hcfmusp.origem.pubmed29345040
hcfmusp.origem.scopus2-s2.0-85046546214
hcfmusp.origem.wosWOS:000431621200003
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBonnin CM, 2016, BRIT J PSYCHIAT, V208, P87, DOI 10.1192/bjp.bp.114.162123
hcfmusp.relation.referenceBonnin CM, 2016, PSYCHOL MED, V46, P291, DOI 10.1017/S0033291715001713
hcfmusp.relation.referenceBonnin CM, 2010, J AFFECT DISORDERS, V121, P156, DOI 10.1016/j.jad.2009.05.014
hcfmusp.relation.referenceBourne C, 2013, ACTA PSYCHIAT SCAND, V128, P149, DOI 10.1111/acps.12133
hcfmusp.relation.referenceBowie CR, 2017, PSYCHIATR REHABIL J, V40, P53, DOI 10.1037/prj0000189
hcfmusp.relation.referenceBreitborde Nicholas Jk, 2014, BMC Psychol, V2, P41, DOI 10.1186/s40359-014-0041-4
hcfmusp.relation.referenceBurdick KE, 2014, PSYCHOL MED, V44, P3083, DOI 10.1017/S0033291714000439
hcfmusp.relation.referenceBurdick KE, 2005, PSYCHIAT RES, V136, P43, DOI 10.1016/j.psychres.2004.12.009
hcfmusp.relation.referenceChen MH, 2015, J AM MED DIR ASSOC, V16, P504, DOI 10.1016/j.jamda.2015.01.084
hcfmusp.relation.referenceda Silva J, 2013, BRIT J PSYCHIAT, V202, P177, DOI 10.1192/bjp.bp.111.101931
hcfmusp.relation.referenceDecker L, 2017, EDORIUM J DISABILITY, V3, P69
hcfmusp.relation.referenceDeckersbach T, 2010, CNS NEUROSCI THER, V16, P298, DOI 10.1111/j.1755-5949.2009.00110.x
hcfmusp.relation.referenceDemant KM, 2015, PSYCHIAT RES, V229, P565, DOI 10.1016/j.psychres.2015.05.022
hcfmusp.relation.referenceDemant KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127955
hcfmusp.relation.referenceDepp CA, 2012, BIPOLAR DISORD, V14, P217, DOI 10.1111/j.1399-5618.2012.01011.x
hcfmusp.relation.referenceDuff K, 2012, ARCH CLIN NEUROPSYCH, V27, P248, DOI 10.1093/arclin/acr120
hcfmusp.relation.referenceForcada I, 2015, EUR NEUROPSYCHOPHARM, V25, P214, DOI 10.1016/j.euroneuro.2014.07.018
hcfmusp.relation.referenceGlahn DC, 2006, J AFFECT DISORDERS, V92, P309, DOI 10.1016/j.jad.2006.01.025
hcfmusp.relation.referenceGomes BC, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1896-5
hcfmusp.relation.referenceGrande I, 2017, J AFFECT DISORDERS, V208, P621, DOI 10.1016/j.jad.2016.10.012
hcfmusp.relation.referenceGrande I, 2016, LANCET, V388, P869
hcfmusp.relation.referenceGualtieri CT, 2008, PROG NEURO-PSYCHOPH, V32, P962, DOI 10.1016/j.pnpbp.2007.12.030
hcfmusp.relation.referenceHarada CN, 2013, CLIN GERIATR MED, V29, P737, DOI 10.1016/j.cger.2013.07.002
hcfmusp.relation.referenceHuxley N, 2007, BIPOLAR DISORD, V9, P183, DOI 10.1111/j.1399-5618.2007.00430.x
hcfmusp.relation.referenceJensen JH, 2016, J AFFECT DISORDERS, V205, P378, DOI 10.1016/j.jad.2016.08.018
hcfmusp.relation.referenceJensen JH, 2015, J AFFECT DISORDERS, V187, P10, DOI 10.1016/j.jad.2015.07.039
hcfmusp.relation.referenceKaser Muzaffer, 2017, Biol Psychiatry Cogn Neurosci Neuroimaging, V2, P115, DOI 10.1016/j.bpsc.2016.11.009
hcfmusp.relation.referenceKogan JN, 2004, BIPOLAR DISORD, V6, P460, DOI 10.1111/j.1399-5618.2004.00158.x
hcfmusp.relation.referenceKupfer DJ, 2002, J CLIN PSYCHIAT, V63, P120, DOI 10.4088/JCP.v63n0206
hcfmusp.relation.referenceKUYKEN W, 1995, SOC SCI MED, V41, P1403
hcfmusp.relation.referenceLewandowski KE, 2017, J CLIN PSYCHIAT, V78, pE1242, DOI 10.4088/JCP.17m11476
hcfmusp.relation.referenceLewandowski KE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1275-7
hcfmusp.relation.referenceLi YL, 2016, ARCH CLIN NEUROPSYCH, V31, P365, DOI 10.1093/arclin/acw017
hcfmusp.relation.referenceMackala SA, 2014, J AFFECT DISORDERS, V168, P119, DOI 10.1016/j.jad.2014.06.045
hcfmusp.relation.referenceMago R, 2014, HARVARD REV PSYCHIAT, V22, P363, DOI 10.1097/HRP.0000000000000017
hcfmusp.relation.referenceMalhi GS, 2016, BIPOLAR DISORD, V18, P102, DOI 10.1111/bdi.12375
hcfmusp.relation.referenceMartinez-Aran A, 2007, BIPOLAR DISORD, V9, P103, DOI 10.1111/j.1399-5618.2007.00327.x
hcfmusp.relation.referenceMarwaha S, 2013, ACTA PSYCHIAT SCAND, V128, P179, DOI 10.1111/acps.12087
hcfmusp.relation.referenceMcIntyre R. S., 2016, INT J NEUROPSYCHOPH, V19, P1
hcfmusp.relation.referenceMeusel LAC, 2013, PSYCHIAT RES-NEUROIM, V214, P142, DOI 10.1016/j.pscychresns.2013.06.007
hcfmusp.relation.referenceMiskowiak KW, 2017, BIPOLAR DISORD, V19, P614, DOI 10.1111/bdi.12534
hcfmusp.relation.referenceMiskowiak KW, 2016, EUR NEUROPSYCHOPHARM, V26, P1845, DOI 10.1016/j.euroneuro.2016.09.641
hcfmusp.relation.referenceMiskowiak KW, 2016, ACTA PSYCHIAT SCAND, V134, P511, DOI 10.1111/acps.12649
hcfmusp.relation.referenceMiskowiak KW, 2014, J CLIN PSYCHIAT, V75, P1347, DOI 10.4088/JCP.13m08839
hcfmusp.relation.referenceMiskowiak KW, 2014, NEUROPSYCHOPHARMACOL, V39, P1399, DOI 10.1038/npp.2013.335
hcfmusp.relation.referenceNaismith SL, 2010, J AFFECT DISORDERS, V121, P258, DOI 10.1016/j.jad.2009.06.028
hcfmusp.relation.referenceOtt C, 2017, TRIALS IN PRESS
hcfmusp.relation.referenceOtt CV, 2016, EUR NEUROPSYCHOPHARM, V26, P1264, DOI 10.1016/j.euroneuro.2016.05.009
hcfmusp.relation.referencePreiss M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00108
hcfmusp.relation.referencePurdon S, 2005, SCREEN COGNITIVE IMP
hcfmusp.relation.referenceRej S, 2018, BIPOLAR DISORD, V20, P359, DOI 10.1111/bdi.12566
hcfmusp.relation.referenceRoebuck-Spencer TM, 2017, ARCH CLIN NEUROPSYCH, V32, P491, DOI 10.1093/arclin/acx021
hcfmusp.relation.referenceRojo E, 2010, SCHIZOPHR RES, V116, P243, DOI 10.1016/j.schres.2009.08.005
hcfmusp.relation.referenceRosa AR, 2013, J AFFECT DISORDERS, V150, P29, DOI 10.1016/j.jad.2013.02.022
hcfmusp.relation.referenceSmith J, 2017, MOL PSYCHIATR, V2017, P1
hcfmusp.relation.referenceSole B, 2016, BIPOLAR DISORD, V18, P288, DOI 10.1111/bdi.12385
hcfmusp.relation.referenceStern RA, 1996, ARCH NEUROL-CHICAGO, V53, P148, DOI 10.1001/archneur.1996.00550020052015
hcfmusp.relation.referenceStrawbridge R, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1472-4
hcfmusp.relation.referenceSvendsen AM, 2012, NORD J PSYCHIAT, V66, P248, DOI 10.3109/08039488.2011.626870
hcfmusp.relation.referenceTorrent C, 2013, AM J PSYCHIAT, V170, P852, DOI 10.1176/appi.ajp.2012.12070971
hcfmusp.relation.referenceTorrent Carla, 2012, J Clin Psychiatry, V73, pe899, DOI 10.4088/JCP.11m07471
hcfmusp.relation.referenceToyoshima K, 2017, PSYCHIAT RES, V254, P85, DOI 10.1016/j.psychres.2017.04.043
hcfmusp.relation.referenceTse S, 2014, BIPOLAR DISORD, V16, P217, DOI 10.1111/bdi.12148
hcfmusp.relation.referenceVan Camp LSC, 2016, COGN NEUROPSYCHIATRY, V21, P130, DOI 10.1080/13546805.2015.1137214
hcfmusp.relation.referenceVeeh J, 2017, INT J BIPOLAR DISORD, V5, DOI 10.1186/s40345-017-0079-3
hcfmusp.relation.referenceVieta E, 2016, WORLD PSYCHIATRY, V15, P288, DOI 10.1002/wps.20351
hcfmusp.relation.referenceWatson S, 2012, BIOL PSYCHIAT, V72, P943, DOI 10.1016/j.biopsych.2012.05.029
hcfmusp.relation.referenceXiao L, 2015, J AFFECT DISORDERS, V173, P226, DOI 10.1016/j.jad.2014.11.011
hcfmusp.relation.referenceYatham LN, 2017, LANCET PSYCHIAT, V4, P208, DOI 10.1016/S2215-0366(17)30046-9
hcfmusp.relation.referenceYatham LN, 2010, BIPOLAR DISORD, V12, P351, DOI 10.1111/j.1399-5618.2010.00830.x
hcfmusp.relation.referenceYen CF, 2008, COMPR PSYCHIAT, V49, P335, DOI 10.1016/j.comppsych.2007.12.006
hcfmusp.relation.referenceYoung AH, 2004, NEUROPSYCHOPHARMACOL, V29, P1538, DOI 10.1038/sj.npp.1300471
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication717693ba-66ff-4dac-9ac5-86d07eafb715
relation.isAuthorOfPublication.latestForDiscovery717693ba-66ff-4dac-9ac5-86d07eafb715
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MISKOWIAK_Assessing_and_addressing_cognitive_impairment_in_bipolar_disorder_2018.PDF
Tamanho:
484.66 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/21